IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG: IDE196
DRUG: Crizotinib
DRUG: Pembrolizumab
DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Dacarbazine

Sponsor

IDEAYA Biosciences